Autologous GVHD following PBSCT, with evidence for a graft-versus-myeloma effect

Bone Marrow Transplantation

Volumn 20, Issue 6, 1997, Pages 517-520

  Byrne, J L ^a,b   Carter, G I ^a   Ellis, I ^a   Haynes, A P ^a   Russell, N H ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Autologous graft versus host disease (GVHD); Graft versus myeloma (GVM) effect; Multiple myeloma; PBSC transplantation

Indexed keywords

CYCLOSPORIN A;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOTRANSPLANTATION; CASE REPORT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; RELAPSE; STEM CELL TRANSPLANTATION;

EID: 0030767772     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700922     Document Type: Article

References (13)

1. Tricot G, Vesole D, Jagannath S, Hilton J. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196-1198.
2. Verdonck LF, Lokhorst H, Dekker A et al. Graft-versus-myeloma effect in 2 cases. Lancet 1996; 347: 800-801.
3. McQuaker IG, Hunter AE, Pacey S et al. Low dose filgrastim significantly enhances neutrophil recovery following autologous peripheral blood stem cell transplantation in patients with lymphoproliferative disorders: evidence for a clinical and economic benefit. J Clin Oncol 1997; 15: 451-457.
4. Kolb H, Mittermuller J, Clemm C et al. Donor leucocyte transfusions for treatment of recurrent chronic myelogenous leukaemia in marrow transplant patients. Blood 1990; 76: 2462-2467.
5. Hood A, Vogelsang G, Black L et al. Acute graft-versus-host disease. Development following autologous and syngeneic bone marrow transplantation. Arch Dermatol 1987; 123: 745-750.
6. Jones R, Vogelsang G, Hess A et al. Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1989; 1: 754-756.
7. Carella A, Gaozza E, Congiu A et al. Cyclosporine-induced graft-versus-host disease after autologous bone marrow transplantation in haematological malignancies. Ann Haematol 1991; 62: 156-159.
8. Kennedy MJ, Beveridge R, Vogelsang GB et al. Survival advantage in breast cancer patients developing GVHD following autologous transplantation. Am Soc Clin Oncol 1991; 10: 43-45.
9. Ratanatharathorn V, Uberti J, Keranes C et al. Phase I study of alpha-interferon augmentation of cyclosporine-induced graft-versus-host disease in recipients of autologous bone marrow transplantation. Bone Marrow Transplant 1994; 13: 625-630.
10. Geller R, Esa A, Beschorner W et al. Successful in vitro graft-versus-tumour effect against an la-bearing tumour using cyclosporine-induced syngeneic graft-versus-host disease in the rat. Blood 1989; 74: 1165-1171.
11. Gryn J, Johnson E, Goldman N et al. Treatment of relapsed or refractory intermediate grade NHL with autologous BMT followed by cyclosporine A and interferon. Bone Marrow Transplant 1997; 19: 221-226.
12. Giralt S, Weber M, Dimopoulos K et al. Phase I trial of cyclosporin A (CsA) induced autologous graft-versus-host disease (GVHD) in patients with multiple myeloma undergoing high dose chemotherapy with autologous stem cell rescue. J Clin Oncol 1997; 15: 667-674.
13. Brown R, Yuen E, Nelson M. Gibson J. T cell clones in myeloma: prognostic significance of T cell receptor beta gene rearrangements and correlation with idiotype-reactive T cells. Blood 1996; 88 (Suppl. 1): (Abstr. 2552).